Elmiron Pigmentary Maculopathy lawsuit settlement criteria
Since our initial coverage of the Elmiron litigation in 2022, the legal landscape surrounding the bladder medication has shifted dramatically. As of early 2026, we are tracking over 3,200 consolidated cases in the multidistrict litigation (MDL) before Judge Robert B. Kugler in the District of New Jersey. The settlement framework established in late 2024 continues to evolve, with new criteria emerging for plaintiffs seeking compensation for pigmentary maculopathy. Here is our updated analysis of the settlement requirements and clinical benchmarks that matter today.
Key Settlement Eligibility Factors Under the 2024-2026 Master Settlement Agreement
The master settlement agreement (MSA) negotiated between Janssen Pharmaceuticals and the Plaintiffs’ Steering Committee sets forth specific criteria that claimants must meet to qualify for compensation. These criteria are not static; we have observed adjustments in 2025 that expanded eligibility for patients with lower cumulative exposure. Below are the core requirements as we understand them in mid-2026:
- Minimum cumulative dose: Claimants must have taken a total of at least 150 grams of pentosan polysulfate sodium (Elmiron) over their treatment history. This typically corresponds to 3-5 years of daily use at standard doses (100 mg three times daily).
- Documented retinal findings: Objective evidence of pigmentary maculopathy via optical coherence tomography (OCT), fundus autofluorescence (FAF), or fluorescein angiography. The MSA requires at least two distinct imaging modalities showing characteristic changes.
- Visual symptom onset: Patients must report at least one of the following: difficulty reading, prolonged dark adaptation, metamorphopsia (distorted vision), or central scotoma. Onset must occur after starting Elmiron and before any alternative diagnosis.
- Exclusion of alternative causes: The settlement excludes patients with pre-existing macular degeneration, Stargardt disease, pattern dystrophy, or other hereditary retinal conditions. A board-certified ophthalmologist must certify the exclusion.
For the most current settlement documents and court filings, we direct readers to the MDL docket available at caudron-simoun.com and the historical archive maintained at archive.org. These resources include the full text of the 2025 amendment that lowered the minimum dose threshold for patients over age 65.
How the Tiered Compensation Structure Works for Elmiron Maculopathy Cases
The settlement employs a tiered system based on objective disease severity, not subjective symptom reports. We have analyzed the payment grids from the 2025 amendment and compiled the following summary of the three primary tiers as they apply to claims filed in 2026:
| Tier | Retinal Findings | Visual Acuity Loss | Estimated Compensation Range |
|---|---|---|---|
| Tier 1 (Mild) | Parafoveal hyperpigmentation on FAF; intact ellipsoid zone on OCT | 20/25 to 20/40 in at least one eye | $75,000 – $150,000 |
| Tier 2 (Moderate) | RPE atrophy extending beyond parafovea; disruption of outer retinal layers | 20/50 to 20/100 in the worse eye | $200,000 – $400,000 |
| Tier 3 (Severe) | Geographic atrophy involving fovea; choroidal neovascularization or fibrosis | 20/200 or worse in the better eye | $500,000 – $1,200,000 |
These figures represent base compensation before deductions for attorneys’ fees (typically 33-40%) and medical liens. We have seen several Tier 3 cases settle at the upper end of the range in 2026, particularly where patients developed bilateral vision loss requiring low-vision rehabilitation services.
The Role of the Elmiron Maculopathy Registry in Settlement Verification
In 2025, the court approved the creation of an independent retinal registry administered by the American Society of Retina Specialists (ASRS). This registry serves as the primary verification mechanism for settlement claims. Claimants must submit their imaging and clinical records to the registry, where three masked readers independently grade the severity using a standardized scale. We have observed that approximately 18% of initial submissions are rejected due to insufficient imaging quality or failure to meet the minimum criteria for pigmentary maculopathy.
The registry also functions as a surveillance tool for ongoing safety monitoring. In January 2026, the ASRS published an interim analysis showing that 72% of registered patients had stable disease after discontinuing Elmiron, while 28% showed progression over a two-year follow-up period. This data has influenced the settlement’s provision for future medical monitoring payments, which we expect to be a subject of continued negotiation through 2027.
For patients who began Elmiron before 2020 and have not yet filed a claim, we strongly recommend obtaining a comprehensive retinal evaluation, including OCT and FAF, even if visual symptoms are minimal. The registry accepts retrospective imaging from as far back as 2018, which can establish baseline disease presence and strengthen a claim under the current MSA terms.